The Investment Whisperer
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Investment Whisperer

Business

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

by admin June 29, 2024
June 29, 2024
Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
France is set for its most consequential election in decades. Here’s what you need to know
next post
YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

Related Posts

How In-N-Out Burger’s president runs her fast-food empire:...

April 19, 2024

Amazon and Nvidia say AI data center demand...

April 25, 2025

Boeing urges inspections of 737 Max planes for...

January 3, 2024

GM ditching ‘Ultium’ name for batteries and tech...

October 10, 2024

Federal Reserve minutes indicate worries over lack of...

May 24, 2024

Microsoft fires back at Delta after massive outage,...

August 8, 2024

Labor groups begin to unite behind Harris’ campaign...

July 25, 2024

‘Inside Out 2’ tops $1 billion at the...

July 2, 2024

23andMe files for bankruptcy as co-founder Anne Wojcicki...

March 25, 2025

Why Honeywell CEO Vimal Kapur doesn’t think the...

October 15, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (1,399)
    • Investing (3,371)
    • Politics (4,552)
    • World (4,488)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheInvestmentWhisperer.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 TheInvestmentWhisperer.com | All Rights Reserved